QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Submission Requirements for Non-Interventional PASS

Test your understanding of the concepts covered by GVP Module VIII Addendum I: Submission of Information on Non-Interventional PASS.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best reflects the distinction between RMP control and regulatory-submission control?

Including a protocol in an RMP automatically fulfils every submission obligation RMP inclusion and regulatory submission are unrelated and should never be linked They are linked governance activities, but RMP attachment does not automatically satisfy a separate submission procedure Regulatory submission is unnecessary whenever a study milestone appears in the RMP

Question 2 of 10 In the framework described by the article, what is the practical significance of the terms "shall" and "should"?

They distinguish scientific documents from administrative documents They distinguish legal requirements from recommendations They distinguish EMA procedures from national procedures They distinguish imposed studies from voluntary studies

Question 3 of 10 What should an MAH establish before creating the submission calendar for a non-interventional PASS?

The preferred electronic portal for uploading the final report The regulatory classification and applicable procedure for the study The date on which the final report is approved internally Whether the study has already been entered in a public register

Question 4 of 10 Why should an MAH track the end of data collection, final report approval and regulatory submission as separate milestones?

They are always performed by different legal entities They represent different regulatory and operational events with different control implications Only final report approval is relevant to pharmacovigilance The end of data collection is an optional project-management date

Question 5 of 10 What is the appropriate role of the QPPV or delegate in relation to a significant PASS submission?

Personally upload every document to every authority Provide or ensure appropriate pharmacovigilance oversight of status, milestones, safety implications and resulting actions Replace the statistician as owner of the analysis Approve national procedural requirements without consulting regulatory specialists

Question 6 of 10 What should the submission record identify to resolve uncertainty about which report version was transmitted?

Only the name of the study sponsor The controlled document version, submission date and procedure or application identifier Only the date on which the report was drafted The names of all employees who reviewed any version

Question 7 of 10 A company calculates the final report deadline from the date of final report approval rather than the end of data collection. What control weakness does this demonstrate?

Failure to distinguish a statutory trigger from an internal project milestone Failure to register the study in the public catalogue Failure to involve the statistician in report drafting Failure to use the latest electronic portal

Question 8 of 10 What is the principal difference between a progress report and a final study report?

A progress report documents study status or interim information, whereas a final report provides the completed scientific assessment A progress report is always legally required, whereas a final report is always voluntary A progress report is submitted only to public registers, whereas a final report is submitted only nationally A progress report can replace the final report when data collection is delayed

Question 9 of 10 A public PASS catalogue contains the protocol and final report, but no evidence of submission to the required authority can be found. What is the main compliance concern?

The scientific validity of the study is automatically invalidated Public transparency has been confused with regulatory submission The study must be reclassified as an imposed PASS The final report must be rewritten solely because it was publicly posted

Question 10 of 10 What is the most resilient way to describe electronic submission requirements in an internal SOP?

Require use of a named portal permanently, regardless of future changes Describe the regulatory transaction first and require verification of the current designated electronic route before submission Permit any portal that generates an automated confirmation Instruct staff to use the same system for all EMA and national submissions

QPPV.com

Knowledge Assessment: Submission Requirements for Non-Interventional PASS

Cookie Settings